Equity Brief · Healthcare2026-05-20
ABBV·Healthcare

AbbVie Inc

I · AI-analyse

In het kort

AbbVie researches, develops, and sells prescription medicines across multiple therapeutic areas. Their biggest focus is immunology drugs (like Skyrizi and Rinvoq) that treat autoimmune diseases, along with cancer treatments (Imbruvica, Venclexta), neuroscience medications (Vraylar, Botox, migraine drugs), and aesthetics products (facial injectables and skincare) [Yahoo Finance]. The company also sells eye care products and treatments for digestive conditions.

AbbVie is a large pharmaceutical company headquartered in Illinois that develops and sells medicines for serious diseases including autoimmune conditions, cancer, neurological disorders, and eye diseases [Yahoo Finance]. The company spun off from Abbott Laboratories in 2013 and now employs 57,000 people worldwide, generating $61.2 billion in annual revenue [Yahoo Finance]. AbbVie is successfully transitioning away from its former blockbuster drug Humira by growing newer products like Skyrizi, Rinvoq, and neuroscience treatments [Yahoo Finance].

AbbVie is financially healthy with strong cash generation, though it carries moderate debt and trades at an unusually high valuation [Yahoo Finance].

In het kort AI analysisBetrouwbaarheid 8/10

Sentinellis-score

7.4/10

Financially healthy

Marktkapitalisatie

$377.7B

Omzet (12 maanden)

$61.2B

II · Recent nieuws

Wat de koers bewoog

6 stories · ranked by relevance

  • macro2026-05-19

    Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

    Zacks

  • macro2026-05-18

    Kernicterus Market Research and Forecast Report 2026-2036 Featuring Pfizer, F.Hoffmann La Roche,. Merck, AbbVie, AsteraZeneca, Abbott Laboratories, Sanofi, GlaxoSmithKline, Grifols

    Yahoo Finance

  • macro2026-05-19

    Polymyositis Market Research Report 2026-2036: Competitive Landscape is Dominated by Major Players Such As Teva Pharmaceuticals, Gilead Sciences, Roche, AbbVie, and Pfizer

    Yahoo Finance

  • macro2026-05-19

    2 Reasons to Like ABBV and 1 to Stay Skeptical

    Yahoo Finance

  • macro2026-05-18

    Here's How Neuroscience Drugs Boost AbbVie's Q1 Sales Growth

    Yahoo Finance

  • macro2026-05-18

    Cannabis Pharmaceuticals Business Research Report 2026: An $111.1 Billion Market by 2032 from $4.7 Billion in 2025 Featuring AbbVie, Aphria, Aurora Cannabis, Bausch Health, and Canopy Growth

    Yahoo Finance

Premium · gratis met elk account

AbbVie generates about half its revenue from immunology treatments, creating significant concentration risk if this single therapeutic area faces competitive pressure or regulatory challenges [Yahoo Finance]

1 van 4 risico's in dit rapport

Risico's

4

Kansen

6

Waarschuwingssignalen

2

Leiding

10

Nog 21 bevindingen in het volledige rapport — gratis met elk account.

Ontgrendel de volledige analyse van AbbVie Inc

Maak een gratis account voor het volledige AI-rapport met bronvermelding in de tekst.

  • 4 risico's, 6 kansen en 2 waarschuwingssignalen — elk met zijn bron
  • Meer dan 100 financiële cijfers met grafieken en vergelijkingen
  • Volledige nieuwssamenvattingen met bronlinks
  • Directie en beloning
  • PDF-export voor offline
Ontgrendel alle 12 bevindingen3 gratis rapporten · geen creditcard

III · Vergelijkbare bedrijven

Misschien ook interessant

Same sector · Healthcare or comparable health

Op je volglijst zetten?

Read three companies free. Geen kaart.

Krijg 3 gratis rapporten